technology

press releases

Date Title and Summary Additional Formats
Toggle Summary Conference call set for 5:00 p.m. EST November 7, 2017 View HTML
Toggle Summary -Clinical data demonstrated that eptinezumab, the only anti-CGRP monoclonal antibody in development administered by quarterly infusion, achieved a preventive benefit on the first day post-infusion and resulted in significant number of days of migraine freedom sustained for three months after first dose- View HTML
Toggle Summary BOTHELL, Wash., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics today announced that it will webcast its presentation at the upcoming Morgan Stanley 15 th Annual Global Healthcare View HTML
Toggle Summary — Positive top-line PROMISE 1 study results  further support eptinezumab's unique clinical profile — — $161.5 million from recent public offering expected to enable continued advancement of eptinezumab through pivotal studies, a planned Biologics License Application and achievement of other key View HTML
Toggle Summary Conference call set for 5:00 p.m. ET August 8, 2017 View HTML
Toggle Summary BOTHELL, Wash., July 18, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 13, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 12, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary BOTHELL, Wash., July 11, 2017 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing its solely-owned pivotal-stage product candidate eptinezumab as the only anti-CGRP monoclonal antibody for the prevention of migraine administered View HTML
Toggle Summary -- Pivotal PROMISE 1 top-line results show eptinezumab met primary and key secondary endpoints -- -- Beginning day 1 after first dose significant reduction in proportion of patients experiencing migraine -- -- Average of 1 in 5 patients had no migraines in any given month over months 1 through 6 -- View HTML